Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUY922 with lapatinib and letrozole in ER+/HER2+ breast cancer
NCT01361945Phase 2
Key facts
- Status
- Withdrawn
- Start
- Jul 2011
- Primary completion
- Aug 2012
- Sponsor
- Texas Tech University Health Sciences Center
- Modality
- Small Molecules
- Drugs
- Luminespib
- Conditions
- breast cancer
01
Overview
Phase 2, open-label trial of Luminespib in breast cancer, sponsored by Texas Tech University Health Sciences Center. Primary endpoint: Overall Response Rate at 104 weeks. Planned start Jul 2011; status: withdrawn.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Endpoints
Primary
Overall Response Rate
Beyond the preview
Go deeper on NCT01361945.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01361945.